Associations of body fat distribution and cardiometabolic risk of testicular cancer survivors after cisplatin-based chemotherapy Journal Article
| Authors: | Wibmer, A. G.; Dinh, P. C. Jr; Travis, L. B.; Chen, C.; Bromberg, M.; Zheng, J.; Capanu, M.; Sesso, H. D.; Feldman, D. R.; Vargas, H. A. |
| Article Title: | Associations of body fat distribution and cardiometabolic risk of testicular cancer survivors after cisplatin-based chemotherapy |
| Abstract: | Background It is unknown how body fat distribution modulates the cardiometabolic risk of testicular cancer survivors after cisplatin-based chemotherapy. Methods For 455 patients enrolled in the Platinum Study at Memorial Sloan Kettering Cancer Center, visceral (VAT) and subcutaneous (SAT) adipose tissue was quantified on prechemotherapy computed tomography. The VAT-to-SAT ratio was calculated as a quantitative measure of central adiposity. Endpoints were incidence of new posthemotherapy cardiometabolic disease (new antihypertensive, lipid-lowering, or diabetes medication), and postchemotherapy Framingham risk scores. Cox models and linear regression with interaction terms were applied. Postchemotherapy body fat distribution was analyzed in 108 patients. All statistical tests were 2-sided. Results The baseline median age was 31 years (interquartile range [IQR] = 26-39 years), body mass index (BMI) was 26 kg/m(2) (IQR = 24-29 kg/m(2)), and the VAT-to-SAT ratio was 0.49 (IQR = 0.31-0.75). The median follow-up was 26 months (IQR = 16-59 months). Higher prechemotherapy VAT-to-SAT ratios inferred a higher likelihood of new cardiometabolic disease among patients with a BMI of 30 kg/m(2) or greater (age-adjusted hazard ratio = 3.14, 95% confidence interval = 1.02 to 9.71, P = .047), but not other BMI groups. The prechemotherapy VAT-to-SAT ratio was associated with postchemotherapy Framingham risk scores in univariate regression analysis (exp(beta)-estimate: 2.10, 95% confidence interval = 1.84 to 2.39, P < .001); in a multivariable model, this association was stronger in younger vs older individuals. BMI increased in most patients after chemotherapy and correlated with increases in the VAT-to-SAT ratio (Spearman r = 0.39, P < .001). Conclusions In testicular cancer survivors, central adiposity is associated with increased cardiometabolic risk after cisplatin-based chemotherapy, particularly in obese or young men. Weight gain after chemotherapy occurs preferentially in the visceral compartment, providing insight into the pathogenesis of cardiovascular disease in this population. |
| Keywords: | mortality; morbidity; obesity; cardiovascular risk; long-term survivors; adults; disease; primary-care; subcutaneous adipose-tissue; profile |
| Journal Title: | JNCI Cancer Spectrum |
| Volume: | 6 |
| Issue: | 4 |
| ISSN: | 2515-5091 |
| Publisher: | Oxford University Press |
| Date Published: | 2022-08-01 |
| Start Page: | pkac030 |
| Language: | English |
| ACCESSION: | WOS:000822053600001 |
| DOI: | 10.1093/jncics/pkac030 |
| PROVIDER: | wos |
| PMCID: | PMC9263534 |
| PUBMED: | 35801305 |
| Notes: | Article -- pkac030 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work